Skip to Main Content

Paper Details

Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.
JCO Precis Oncol
63
2019
Anti-Epidermal Growth Factor Receptor Antibody, EGFRab, Metastatic Colorectal Cancer, anti-, anti-EGFRab, anti-EGFRabs, anti-epidermal growth factor receptor antibodies, mCRC, metastatic colorectal cancer, patients, tumor, tumor tissue, wild
Author NameAffiliation
Jeffrey S MorrisThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Jeffrey S MorrisThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Mark J RoutbortThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Ken ChenThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Kenna R Mills ShawThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Kenna R Mills ShawThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
Scott KopetzThe University of Texas MD Anderson Cancer Center, City of Hope Comprehensive Cancer Center
  • 1 - 8

Datasets

Release 1.2